Literature DB >> 1691563

Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1.

D Schols1, R Pauwels, J Desmyter, E De Clercq.   

Abstract

Eighty to 100% of persistently HIV-1-infected HUT-78 cells express the viral glycoprotein gp120 as demonstrated with anti-gp 120 monoclonal antibody (mAb) and fluorescence-activated cell sorter (FACS) analysis. Several polyanionic anti-HIV compounds, i.e., dextran sulfate, pentosan polysulfate, heparin, aurintricarboxylic acid (ATA), suramin, and Evans blue, which are known to inhibit the adsorption of HIV particles to CD4+ cells, prevented the binding of anti-gp120 mAb to the persistently HIV-1 infected HUT-78 cells. This effect was dose-dependent and reversible. Except for ATA, the polyanionic compounds did not interfere with the binding of Leu3a/OKT4A mAB, indicating that they do not directly bind to the CD4 receptor. Thus, the inhibitory effect of dextran sulfate and its congeners on the interaction of the HIV gp120 with the cellular CD4 receptor can be ascribed to a specific binding ("shielding") of gp120.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691563     DOI: 10.1016/0042-6822(90)90440-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  39 in total

1.  Enzymatic kinetic studies with the non-nucleoside HIV reverse transcriptase inhibitor U-9843.

Authors:  I W Althaus; R J LeMay; A J Gonzales; M R Deibel; S K Sharma; F J Kezdy; L Resnick; M E Busso; P A Aristoff; F Reusser
Journal:  Experientia       Date:  1992-12-01

2.  Critical design features of phenyl carboxylate-containing polymer microbicides.

Authors:  Robert F Rando; Sakae Obara; Mark C Osterling; Marie Mankowski; Shendra R Miller; Mary L Ferguson; Fred C Krebs; Brian Wigdahl; Mohamed Labib; Hiroyasu Kokubo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.

Authors:  J Balzarini; D Schols; J Neyts; E Van Damme; W Peumans; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE).

Authors:  D Schols; P Proost; J Van Damme; E De Clercq
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin.

Authors:  X J Yao; M A Wainberg; M Richard; M Pollak
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 7.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

Review 8.  Protein-glycosaminoglycan interactions: infectiological aspects.

Authors:  D Sawitzky
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

Review 9.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

10.  Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

Authors:  Jan Balzarini; Sigrid Hatse; Kurt Vermeire; Katrien Princen; Stefano Aquaro; Carlo-Federico Perno; Erik De Clercq; Herman Egberink; Guy Vanden Mooter; Willy Peumans; Els Van Damme; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.